New Whitepaper Proposes Flexibility, Technology, and Innovation to Extend Lifespan of Biopharmaceutical Facilities

The distinctive design proposed in this new whitepaper will allow future life sciences facilities to morph into whatever size or form is needed and no longer become obsolete after 15-20 years.

The Industrial Asset Management Council (IAMC) and the Society of Industrial and Office Realtors (SIOR) have released their second whitepaper in the DesignFlex2030 initiative titled “Rx for Change: The Flexible Biopharma Facility of the Future.” The paper outlines creative and practical suggestions on how to extend the lifecycle of future biopharmaceutical facilities so they can be repurposed quickly, efficiently, and cost-effectively for rapid scale-up and scale-down, technological change, scientific breakthroughs, and process innovation.

The whitepaper addresses the problems with biopharmaceutical facilities that are built for today’s use, with no thought about the future. New life sciences production facilities can cost anywhere from $500 million to upwards of $1 billion. They are typically built around a single product and can’t be easily reconfigured, so they are often unusable after just 15-20 years. Whenever companies bring a new drug to market the process starts over, and they invest millions more in new facilities and equipment. Reselling aging and unwanted pharma real estate represents a challenge to both the owners and economic developers, who may have a hard time attracting new users due to the lack of flexibility.

“The distinctive design proposed in this new whitepaper incorporates the latest thinking in industrial design and workflow efficiency and will help companies attract and retain the highly educated talent they will need to retain their competitive edge going forward,” said Tate Godfrey, Executive Director, IAMC. “Such upgrades…

Read the full article from the author…

Back to Top